- Home
- CRIS vs PULM Comparison
CRIS vs PULM Comparison
Compare CRIS & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- PULM
- Stock Information
- Founded
- CRIS 2000
- PULM 2003
- Country
- CRIS United States
- PULM United States
- Employees
- CRIS N/A
- PULM N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- PULM Health Care
- Exchange
- CRIS Nasdaq
- PULM Nasdaq
- Market Cap
- CRIS 32.8M
- PULM 30.9M
- IPO Year
- CRIS 2000
- PULM N/A
- Fundamental
- Price
- CRIS $1.48
- PULM $6.14
- Analyst Decision
- CRIS Strong Buy
- PULM
- Analyst Count
- CRIS 3
- PULM 0
- Target Price
- CRIS $21.00
- PULM N/A
- AVG Volume (30 Days)
- CRIS 51.0K
- PULM 21.3K
- Earning Date
- CRIS 03-31-2025
- PULM 05-09-2025
- Dividend Yield
- CRIS N/A
- PULM N/A
- EPS Growth
- CRIS N/A
- PULM N/A
- EPS
- CRIS N/A
- PULM N/A
- Revenue
- CRIS $10,908,000.00
- PULM $7,806,000.00
- Revenue This Year
- CRIS N/A
- PULM N/A
- Revenue Next Year
- CRIS $27.88
- PULM $134.88
- P/E Ratio
- CRIS N/A
- PULM N/A
- Revenue Growth
- CRIS 8.83
- PULM 6.96
- 52 Week Low
- CRIS $1.42
- PULM $1.68
- 52 Week High
- CRIS $17.49
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- CRIS 18.52
- PULM 37.17
- Support Level
- CRIS $2.57
- PULM $7.16
- Resistance Level
- CRIS $2.62
- PULM $7.33
- Average True Range (ATR)
- CRIS 0.26
- PULM 0.53
- MACD
- CRIS -0.07
- PULM -0.15
- Stochastic Oscillator
- CRIS 10.88
- PULM 5.00
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.